Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study
Journal
Allergy
Journal Volume
77
Journal Issue
7
Pages
2175
Date Issued
2022
Author(s)
Maurer, Marcus
Giménez-Arnau, Ana
Bernstein, Jonathan A
Danilycheva, Inna
Hide, Michihiro
et al.,
Abstract
Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as a treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled with standard-of-care therapy.
Subjects
IgE; chronic spontaneous urticaria; ligelizumab; omalizumab; urticaria
SDGs
Publisher
WILEY
Type
journal article